216 related articles for article (PubMed ID: 16234409)
1. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
[TBL] [Abstract][Full Text] [Related]
3. A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor.
Thibonnier M; Coles P; Conarty DM; Plesnicher CL; Shoham M
J Pharmacol Exp Ther; 2000 Jul; 294(1):195-203. PubMed ID: 10871312
[TBL] [Abstract][Full Text] [Related]
4. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
[TBL] [Abstract][Full Text] [Related]
5. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.
Serradeil-Le Gal C; Wagnon J; Simiand J; Griebel G; Lacour C; Guillon G; Barberis C; Brossard G; Soubrié P; Nisato D; Pascal M; Pruss R; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2002 Mar; 300(3):1122-30. PubMed ID: 11861823
[TBL] [Abstract][Full Text] [Related]
6. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
[TBL] [Abstract][Full Text] [Related]
7. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Robben JH; Sze M; Knoers NV; Deen PM
Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule vasopressin-2 receptor antagonist identified by a g-protein coupled receptor "pathway" screen.
Yangthara B; Mills A; Chatsudthipong V; Tradtrantip L; Verkman AS
Mol Pharmacol; 2007 Jul; 72(1):86-94. PubMed ID: 17435162
[TBL] [Abstract][Full Text] [Related]
10. Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
Betz SF; Reinhart GJ; Lio FM; Chen C; Struthers RS
J Med Chem; 2006 Jan; 49(2):637-47. PubMed ID: 16420049
[TBL] [Abstract][Full Text] [Related]
11. Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8.
Jensen PC; Nygaard R; Thiele S; Elder A; Zhu G; Kolbeck R; Ghosh S; Schwartz TW; Rosenkilde MM
Mol Pharmacol; 2007 Aug; 72(2):327-40. PubMed ID: 17652183
[TBL] [Abstract][Full Text] [Related]
12. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.
Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR
Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139
[TBL] [Abstract][Full Text] [Related]
13. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
[TBL] [Abstract][Full Text] [Related]
14. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
Frantz MC; Rodrigo J; Boudier L; Durroux T; Mouillac B; Hibert M
J Med Chem; 2010 Feb; 53(4):1546-62. PubMed ID: 20104850
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
Acta Biochim Pol; 1998; 45(1):19-26. PubMed ID: 9701492
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
17. Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.
Derick S; Pena A; Durroux T; Wagnon J; Serradeil-Le Gal C; Hibert M; Rognan D; Guillon G
Mol Endocrinol; 2004 Nov; 18(11):2777-89. PubMed ID: 15284336
[TBL] [Abstract][Full Text] [Related]
18. Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
Cussac D; Palmier C; Finana F; De Vries L; Tardif S; Léger C; Bernois S; Heusler P
J Pharmacol Exp Ther; 2009 Oct; 331(1):222-33. PubMed ID: 19605522
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
20. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
Gimpl G; Postina R; Fahrenholz F; Reinheimer T
Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
